Emerging Company Profile
RayzeBio pulling together radiotherapy platform with $45 million
RayzeBio combines the tumor-killing of actinium 225 with the target affinity and PK of macrocycles
RayzeBio is combining the tumor-killing potency of actinium 225 with the target affinity and PK of macrocycles.
RayzeBio thinks its targeting and radioisotope strategies can take radiopharmaceuticals from a series of individual success stories to a broadly applicable platform technology for cancer.